HazMat Fee + There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.
| Type | HazMat fee for 500 gram (Estimated) |
| Excepted Quantity | USD 0.00 |
| Limited Quantity | USD 15-60 |
| Inaccessible (Haz class 6.1), Domestic | USD 80+ |
| Inaccessible (Haz class 6.1), International | USD 150+ |
| Accessible (Haz class 3, 4, 5 or 8), Domestic | USD 100+ |
| Accessible (Haz class 3, 4, 5 or 8), International | USD 200+ |


| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解

| 产品名称 | 5-HT ↓ ↑ | 5-HT1 ↓ ↑ | 5-HT2 ↓ ↑ | 5-HT3 ↓ ↑ | 5-HT5 ↓ ↑ | 5-HT6 ↓ ↑ | 5-HT7 ↓ ↑ | 其他靶点 | 纯度 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Desvenlafaxine |
++
5-HT, Ki: 40.2 nM |
98% | |||||||||||||||||
| Lamotrigine |
+
5-HT (rat brain synaptosomes), IC50: 474 μM 5-HT (human platelets), IC50: 240 μM |
98% | |||||||||||||||||
| Venlafaxine | ✔ | 99% | |||||||||||||||||
| Fluvoxamine maleate | ✔ | 99% | |||||||||||||||||
| Iloperidone | ✔ | 99% | |||||||||||||||||
| Ziprasidone HCl | ✔ | 98+% | |||||||||||||||||
| Atomoxetine HCI |
+
5-HT, Ki: 77 nM |
98% | |||||||||||||||||
| Dapoxetine HCl | ✔ | 97% | |||||||||||||||||
| Trazodone | ✔ | 98+% | |||||||||||||||||
| Clomipramine HCl | ✔ | 98% | |||||||||||||||||
| Mirtazapine | ✔ | 99+% | |||||||||||||||||
| Escitalopram oxalate |
+++
5-HT, Ki: 0.89 nM |
97% | |||||||||||||||||
| Duloxetine | ✔ | 97% | |||||||||||||||||
| Sertraline HCl |
++
5-HT, Ki: 13 nM |
98% | |||||||||||||||||
| Citalopram HBr |
+++
serotonin reuptake, IC50: 1.8 nM |
98% | |||||||||||||||||
| Latrepirdine 2HCl | ✔ | GluR | 99% | ||||||||||||||||
| Fluoxetine HCl | ✔ | 99.5% | |||||||||||||||||
| Paroxetine HCl | ✔ | AChR | 99% | ||||||||||||||||
| BMY 7378 |
++
5-HT1D, pIC50: 5.9 5-HT1A, pIC50: 6.4 |
+
5-HT2, pIC50: 5.5 |
97% | ||||||||||||||||
| Flibanserin |
+++
5-HT1A, Ki: 1 nM |
+
5-HT2A, Ki: 49 nM |
95% | ||||||||||||||||
| LY310762 |
+
5-HT1D, Ki: 249 nM |
99%+ | |||||||||||||||||
| Cyclobenzaprine HCI | ✔ | 99% | |||||||||||||||||
| Blonanserin |
+++
5-HT2, Ki: 3.98 nM |
99% | |||||||||||||||||
| Cyproheptadine HCl |
++++
5-HT2, IC50: 0.6 nM |
99+% | |||||||||||||||||
| Olanzapine | ✔ | 99+% | |||||||||||||||||
| Pimavanserin hemitartrate |
+++
5-HT2A, pIC50: 8.7 |
99% | |||||||||||||||||
| Ketanserin |
+++
5-HT2C (Human), Ki: 2.5 nM 5-HT2C (Rat), Ki: 50 nM |
99%+ | |||||||||||||||||
| Loxapine succinate |
++
5-HT2 (bovine), Ki: 6.6 nM 5-HT2 (human), Ki: 6.8 nM |
98% | |||||||||||||||||
| Agomelatine | ✔ | 98% | |||||||||||||||||
| Clozapine | ✔ | 98% | |||||||||||||||||
| Amitriptyline |
+
5-HT2, Ki: 235 nM |
SERT | 99% | ||||||||||||||||
| PRX-08066 maleate |
+++
5-HT2B, IC50: 3.4 nM |
98+% | |||||||||||||||||
| RS-127445 |
++++
5-HT2B, pKi: 9.5 5-HT2B, pIC50: 10.4 |
99%+ | |||||||||||||||||
| Sarpogrelate HCl |
++++
5-HT2C, Kd: 1.1 nM 5-HT2A, Kd: 2.1 nM |
98% | |||||||||||||||||
| Tropisetron | ✔ | 99% | |||||||||||||||||
| Ramosetron HCl |
++++
5-HT3 receptor, Ki: 0.091 nM |
98% | |||||||||||||||||
| Ondansetron | ✔ | 99% | |||||||||||||||||
| Granisetron | ✔ | 98% | |||||||||||||||||
| Alosetron HCl | ✔ | 98% | |||||||||||||||||
| Ondansetron HCl dihydrate | ✔ | 98% | |||||||||||||||||
| VUF10166 |
++++
5-HT3AB, Ki: 22 nM 5-HT3A, Ki: 0.04 nM |
99%+ | |||||||||||||||||
| Azasetron HCl |
++++
5-HT3, IC50: 0.33 nM |
99% | |||||||||||||||||
| Asenapine maleate |
+++
5-HT1B, pKi: 8.4 5-HT1A, pKi: 8.6 |
++++
5-HT2A, pKi: 9.75 5-HT2C, pKi: 10.46 |
+++
5-HT5A, pKi: 8.84 |
++++
5-HT6, pKi: 9.6 |
++++
5-HT7, pKi: 9.94 |
97% | |||||||||||||
| Risperidone |
++
5-HT1D, Ki: 84.6 nM 5-HT1B, Ki: 14.9 nM |
++++
5-HT2A, Ki: 61.9 nM 5-HT2C, Ki: 12 nM |
+
5-HT5A, Ki: 206 nM |
++
5-HT7, Ki: 6.6 nM |
98% | ||||||||||||||
| SB 271046 HCl |
+++
5-HT6, pKi: 8.92 |
99%+ | |||||||||||||||||
| Intepirdine |
++++
5-HT6, pKi: 9.63 |
99%+ | |||||||||||||||||
| SB-269970 HCl |
++
5-HT7, pKi: 8.3 |
98+% | |||||||||||||||||
| BRL 15572 |
++
5-HT1B, pKi: 6.1 5-HT1D, pKi: 6 |
++
5-HT2A, pKi: 6.6 5-HT2B, pKi: 6.2 |
+
5-HT6, pKi: 5.9 |
+
5-HT7, pKi: 6.3 |
95% | ||||||||||||||
| 1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 | |||||||||||||||||||
| 产品名称 | D1 receptor ↓ ↑ | D2 receptor ↓ ↑ | D3 receptor ↓ ↑ | D4 receptor ↓ ↑ | D5 receptor ↓ ↑ | DAT ↓ ↑ | Dopamine receptor ↓ ↑ | 其他靶点 | 纯度 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Penfluridol |
+
Dopamine receptor, Ki: 1.6 μM |
98% | |||||||||||||||||
| Ansofaxine HCl |
++
Dopamine receptor, IC50: 491 nM |
99% | |||||||||||||||||
| Tetrahydroberberine |
+
D2 receptor, pKi: 6.08 |
98+% | |||||||||||||||||
| Prochlorperazine Maleate | ✔ | 98% (HPLC) | |||||||||||||||||
| Olanzapine | ✔ | 99+% | |||||||||||||||||
| Trifluoperazine |
++++
Dopamine D2 receptor, IC50: 1.1 nM |
98% | |||||||||||||||||
| Ropinirole HCl |
++
D2 receptor, Ki: 29 nM |
99% | |||||||||||||||||
| Lurasidone |
++++
D2 receptor, Ki: 1 nM |
98% | |||||||||||||||||
| Levosulpiride | ✔ | 99+% | |||||||||||||||||
| Pridopidine | ✔ | 95% | |||||||||||||||||
| Metoclopramide | ✔ | ✔ | 99+% | ||||||||||||||||
| Molindone HCl | ✔ | 99% | |||||||||||||||||
| Sulpiride | ✔ | 99+% | |||||||||||||||||
| Perospirone |
++++
D2 receptor, Ki: 1.4 nM |
99% | |||||||||||||||||
| Perospirone HCl |
++++
D2 receptor, Ki: 1.4 nM |
99% | |||||||||||||||||
| Phenothiazine | ✔ | 98% | |||||||||||||||||
| Pimozide |
+
Dopamine D1 receptor, Ki: 6600 nM |
+++
Dopamine D2 receptor, Ki: 3.0 nM |
++++
Dopamine D3 receptor, Ki: 0.83 nM |
98% | |||||||||||||||
| Rotundine |
++
D1 receptor, IC50: 166 nM |
+
D2 receptor, IC50: 1.47 μM |
+
D3 receptor, IC50: 3.25 μM |
98% | |||||||||||||||
| Domperidone | ✔ | 99+% | |||||||||||||||||
| ONC206 | ✔ | 99% | |||||||||||||||||
| Pimethixene maleate |
++
Dopamine D1 Receptor, pKi: 6.37 |
+++
Dopamine D2 Receptor, pKi: 8.19 |
++
Dopamine D4.4 Receptor, pKi: 7.54 |
97% | |||||||||||||||
| Loxapine succinate |
++
D1 receptor (human), Ki: 26 nM D2 receptor (Human), Ki: 62 nM |
++
D2 receptor (human), Ki: 24 nM D2 receptor (bovine), Ki: 26 nM |
+++
D4 receptor (human), Ki: 7.5 nM |
98% | |||||||||||||||
| Chlorprothixene |
+++
D1 receptor, Ki: 18 nM |
+++
D2 receptor, Ki: 2.96 nM |
+++
D3 receptor, Ki: 4.56 nM |
+++
D5 receptor, Ki: 9 nM |
99% | ||||||||||||||
| SCH-23390 HCl |
++++
D1 dopamine receptor, Ki: 0.2 nM |
++++
D5 dopamine receptor, Ki: 0.3 nM |
98% | ||||||||||||||||
| MPP+ iodide | ✔ | 97% | |||||||||||||||||
| σ1 Receptor antagonist-1 |
+
DAT, pKi: 5.8 |
97% | |||||||||||||||||
| Benztropine mesylate |
++
DAT, IC50: 118 nM |
98% | |||||||||||||||||
| Azaperone | ✔ | 98% | |||||||||||||||||
| Ziprasidone HCl | ✔ | 98+% | |||||||||||||||||
| Paliperidone | ✔ | 98% | |||||||||||||||||
| Alizapride HCl | ✔ | 99+% | |||||||||||||||||
| Amisulpride | ✔ | 98% | |||||||||||||||||
| Quetiapine hemifumarate | ✔ | Adrenergic Receptor | 98% | ||||||||||||||||
| Clozapine N-oxide | ✔ | 99% | |||||||||||||||||
| 1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 | |||||||||||||||||||
| 靶点 |
|
| 描述 | Olanzapine is a D2 dopamine receptor antagonist with a high affinity for 5-HT2 serotonin. In vivo, sequential doses of olanzapine at 0.5, 3 and 10 mg/kg dose-dependently increased the extracellular dopamine (DA) and norepinephrine (NE) levels in all three brain areas. The increases appeared 30 min after olanzapine administration, reached peaks around 60 - 90 min and lasted for at least 2 h[3]. The high dose of olanzapine (10 mg/kg ) increased the number of fos-like positive nuclei in mesolimbic areas connected to the extended amygdala[4]. In vitro, olanzapine interacted with keyreceptorsof interest in schizophrenia, exihibiting a nanomolar affinity for dopaminergic, serotonergic, alpha 1-adrenergic, and muscarinic receptors[5]. |
| Concentration | Treated Time | Description | References | |
| MIN6 cells | 50 µM | 14 hours | Olanzapine partially inhibited mastoparan-induced insulin secretion | Elife. 2020 Nov 17;9:e60970. |
| 3T3-L1 adipocytes | 5 µM | 0, 12, 24, 48 and 72 hours | Olanzapine inhibited insulin-stimulated glucose uptake over time, reaching maximum inhibition at 48 hours | Sci Rep. 2019 Feb 7;9(1):1582. |
| HEK293T cells | 150 µM | 24 hours | To evaluate the effect of olanzapine on mitophagy, results showed that olanzapine decreased the formation of mitolysosomes. | Aging Cell. 2023 Nov;22(11):e14003. |
| HEK293T cells | 150 µM | 24 hours | To evaluate the effect of olanzapine on mitochondrial parameters, results showed that olanzapine increased mitochondrial ROS levels, mitochondrial contents, and mitochondrial membrane potential. | Aging Cell. 2023 Nov;22(11):e14003. |
| PC12 cells | 0, 10, 20, 40 µM | 24 hours | To investigate whether olanzapine activated AMPK, results showed that olanzapine increased the phosphorylation of AMPK in both dose- and time-dependent manners | Acta Pharmacol Sin. 2020 Apr;41(4):508-515. |
| U87 cells | 0-400 µM | 24, 48, 72 hours | Evaluate the inhibitory effects of olanzapine on the growth of glioma cells, showing that olanzapine significantly inhibits the growth of glioma cells in a dose- and time-dependent manner. | CNS Neurosci Ther. 2019 Sep;25(9):911-921. |
| LN229 cells | 0-400 µM | 24, 48, 72 hours | Evaluate the inhibitory effects of olanzapine on the growth of glioma cells, showing that olanzapine significantly inhibits the growth of glioma cells in a dose- and time-dependent manner. | CNS Neurosci Ther. 2019 Sep;25(9):911-921. |
| T98 cells | 0-400 µM | 24, 48, 72 hours | Evaluate the inhibitory effects of olanzapine on the growth of glioma cells, showing that olanzapine significantly inhibits the growth of glioma cells in a dose- and time-dependent manner. | CNS Neurosci Ther. 2019 Sep;25(9):911-921. |
| MIN6 cells | 10-50 µM | 4 hours or 14 hours | Olanzapine inhibited glucose-stimulated insulin secretion in a concentration-dependent manner | Elife. 2020 Nov 17;9:e60970. |
| PC12 cells | 20 µM | 48 hours | To investigate the effect of olanzapine on autophagy, results showed that olanzapine induced autophagy and increased autophagic vacuoles | Acta Pharmacol Sin. 2020 Apr;41(4):508-515. |
| 3T3-L1 adipocytes | 0, 1, 2, 5, or 10 µM | 48 hours | Olanzapine dose-dependently inhibited insulin-stimulated glucose uptake, increased NF-κB activity and decreased IκBα protein expression | Sci Rep. 2019 Feb 7;9(1):1582. |
| Administration | Dosage | Frequency | Description | References | ||
| Balb/c mice and Sprague Dawley rats | Insulin resistance model | Intraperitoneal injection | 10 mg/kg | Once daily for 8 weeks | Chronic olanzapine treatment caused metabolic symptoms, including insulin resistance, by markedly elevating plasma pro-inflammatory cytokine levels | Sci Rep. 2019 Feb 7;9(1):1582. |
| Caenorhabditis elegans | Wild-type N2 | Administered via NGM medium | 25, 50, 100, 150, 300 μM | From the L4 larval stage until death | To evaluate the effect of olanzapine on lifespan, results showed that olanzapine significantly shortened the lifespan of C. elegans. | Aging Cell. 2023 Nov;22(11):e14003. |
| Mice | BALB/c mice | Oral | 3 mg/kg/day or 10 mg/kg/day | Once a day for 1-6 weeks | Olanzapine induced proinsulin misfolding in mouse islets | Elife. 2020 Nov 17;9:e60970. |
| Female Sprague-Dawley rats | Methylazoxymethanol (MAM)-induced neurodevelopmental model of schizophrenia | Intramuscular injection | 5 mg/kg | Acute administration, observed over 24 hours | To investigate the acute metabolic effects of olanzapine and haloperidol in the MAM model, finding that olanzapine induced pronounced serum lipid profile alterations in MAM rats, while haloperidol had weaker metabolic effects. | CNS Neurosci Ther. 2024 Feb;30(2):e14565 |
| Wistar rats | Chronic social isolation model | Intraperitoneal injection | 7.5 mg/kg/day | Once daily for 3 weeks | To investigate the effects of Olz on the number of PV+ and GAD67+ cells in the hippocampus of CSIS rats and its antioxidative and anti-inflammatory potential. Olz reversed CSIS-induced depressive-like behavior, increased the number of GAD67+ cells in the SO and SP layers of dCA1, reduced the number of PV+ and GAD67+ cells in the SR layer of dCA3, and modulated oxidative stress and inflammatory markers. | Int J Mol Sci. 2023 Dec 6;24(24):17181 |
| 计算器 | ||||
| 存储液制备 | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
3.20mL 0.64mL 0.32mL |
16.00mL 3.20mL 1.60mL |
32.01mL 6.40mL 3.20mL |
|
| CAS号 | 132539-06-1 |
| 分子式 | C17H20N4S |
| 分子量 | 312.43 |
| SMILES Code | CC1=CC(C(N2CCN(C)CC2)=N3)=C(S1)NC4=C3C=CC=C4 |
| MDL No. | MFCD00866702 |
| 别名 | LY170053 |
| 运输 | 蓝冰 |
| InChI Key | KVWDHTXUZHCGIO-UHFFFAOYSA-N |
| Pubchem ID | 135398745 |
| 存储条件 |
In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Keep in dark place, sealed in dry, 2-8°C |
| 溶解方案 |
DMSO: 18 mg/mL(57.61 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|
沪公网安备 31011702889066号
沪ICP备2024050318号-1